Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid

Novartis

Status and phase: Completed; Phase 3

Conditions: Osteoporosis

Treatments: Drug: zoledronic acid

Study type: Interventional

Funder types: Industry

Identifiers

NCT00097812

CZOL446H2313

Details and patient eligibility

About

The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.

Sex: Female

Ages: 45 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Post-menopausal women between 45 and 79 years of age
• Must be osteopenic/osteoporotic
• Treatment with oral bisphosphonate for at least 1 year

Exclusion criteria

• Any woman of child bearing potential
• Treatment with other bone active agents

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind